Clinical Trial: Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation

Study Status: Completed
Recruit Status: Completed
Study Type: Observational

Official Title: Longitudinal Study of Immune Mediated Disorders After Allogeneic Hematopoietic Cell Transplantation (HCT)

Brief Summary: The purpose of this research study is to better understand the onset and course of graft versus host disease (GVHD)and other immune-mediated disorders after stem cell transplant.

Detailed Summary:

Allogeneic hematopoietic cell transplantation (HCT) is the only known curative option for many hematologic disorders. After transplantation, many patients develop immune mediated disorders that may be life-threatening such as graft versus host disease (GVHD). The morbidity and mortality associated with HCT-associated immune mediated disorders are major barriers to successful use of transplantation to cure rare hematologic malignancies such as leukemia, lymphoma, multiple myeloma, myelodysplastic/myeloproliferative syndromes amongst other diseases.

With this study, the investigators will investigate the biologic basis for immune mediated disorders after allogeneic HCT, focusing on those developing cutaneous sclerosis, bronchiolitis obliterans syndrome, late acute GVHD and chronic GVHD. The study will enroll 1118 (1018 adults and 100 children) allogeneic HCT patients over a three year period. Subjects will be followed for two years and monitored closely for development of immune mediated disorders. This study will have 5 study visits at day 1, 100, 180, 365, and 730. During these visits, a physical assessment, medication review, blood and urine collection will occur.

If a subject develops an immune mediated disordered, they will be monitored at 3 months, 6 months, 1 year and then annually from the date of diagnosis. During these study visits, a physical assessment, IMD status, and medication review as well as blood and urine collection will occur.


Sponsor: Fred Hutchinson Cancer Research Center

Current Primary Outcome: The prevalence of immune mediated disorders [ Time Frame: Diagnosis of IMD and at 2 years ]

The prevalence of:

  • Persistent, recurrent or late onset acute GVHD
  • Cutaneous Sclerosis
  • Bronchiolitis Obliterans Syndrome
  • Chronic GVHD


Original Primary Outcome: The prevalence of immune mediated disorders [ Time Frame: The time of diagnosis and at two years ]

The prevalence of:

  • Persistent, recurrent or late onset acute GVHD
  • Cutaneous Sclerosis
  • Bronchiolitis Obliterans Syndrome
  • Chronic GVHD


Current Secondary Outcome: Banked blood and urine samples [ Time Frame: At 2 years ]

Summarized as the percentage of compliance for each center and for the study as a whole


Original Secondary Outcome: Banked blood and urine samples [ Time Frame: At the end of the study ]

Summarized as the percentage of compliance for each center and for the study as a whole


Information By: Fred Hutchinson Cancer Research Center

Dates:
Date Received: September 20, 2010
Date Started: March 2011
Date Completion:
Last Updated: October 6, 2016
Last Verified: October 2016